Jennifer Nam

509 total citations
16 papers, 339 citations indexed

About

Jennifer Nam is a scholar working on Hematology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Jennifer Nam has authored 16 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 6 papers in Psychiatry and Mental health and 5 papers in Molecular Biology. Recurrent topics in Jennifer Nam's work include Multiple Myeloma Research and Treatments (6 papers), Bipolar Disorder and Treatment (6 papers) and Electroconvulsive Therapy Studies (3 papers). Jennifer Nam is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Bipolar Disorder and Treatment (6 papers) and Electroconvulsive Therapy Studies (3 papers). Jennifer Nam collaborates with scholars based in United States, Canada and Poland. Jennifer Nam's co-authors include Sheri L. Johnson, Jutta Joormann, Charles S. Carver, Youngmee Kim, Jenifer L. Culver, Terence A. Ketter, Kristine L. Keller, June Gruber, Todd M. Zimmerman and Cara A. Rosenbaum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Psychological Science.

In The Last Decade

Jennifer Nam

16 papers receiving 333 citations

Peers

Countries citing papers authored by Jennifer Nam

Since Specialization

Citations

This map shows the geographic impact of Jennifer Nam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Nam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Nam more than expected).

Fields of papers citing papers by Jennifer Nam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Nam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Nam. The network helps show where Jennifer Nam may publish in the future.

Co-authorship network of co-authors of Jennifer Nam

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Nam. A scholar is included among the top collaborators of Jennifer Nam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Nam. Jennifer Nam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Detection of arterial pressure waveform error using machine learning trained algorithms 2021 ·Journal of Clinical Monitoring and Computing ·Joseph Rinehart, (unknown), Jennifer Nam, (unknown), (unknown), (unknown), (unknown), (unknown), Alexandre Joosten	2
2	Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma 2019 ·British Journal of Haematology ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Craig E. Cole, Ajai Chari, Joseph Mıkhael, Jennifer Nam, (unknown), (unknown), (unknown), (unknown), Shaun Rosebeck, Todd M. Zimmerman, (unknown), (unknown), Theodore Karrison, Jeffrey A. Zonder	55
3	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) 2016 ·Blood ·Todd M. Zimmerman, Noopur Raje, Ravi Vij, Donna Reece, Jesús G. Berdeja, (unknown), Kathryn McDonnell, Cara A. Rosenbaum, Jagoda Jasielec, Paul G. Richardson, Sandeep Gurbuxani, Jennifer Nam, (unknown), (unknown), Shaun Rosebeck, Andrew Stefka, Dominik Dytfeld, Kent A. Griffith, Andrzej Jakubowiak	41
4	Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. 2016 ·Journal of Clinical Oncology ·Cara A. Rosenbaum, (unknown), Vishal Kukreti, Jeffrey A. Zonder, Craig E. Cole, Todd M. Zimmerman, Donna Reece, Jesús G. Berdeja, (unknown), (unknown), (unknown), Kathryn McDonnell, Jennifer Nam, Kent A. Griffith, Andrzej Jakubowiak	7
5	Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimid®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) 2016 ·Biology of Blood and Marrow Transplantation ·Todd M. Zimmerman, Kent A. Griffith, Jagoda Jasielec, Cara A. Rosenbaum, Jesús G. Berdeja, Ravi Vij, Noopur Raje, Donna Reece, David H. Vesole, Sundar Jagannath, Mark Kaminski, Craig E. Cole, Jennifer Nam, (unknown), Shaun Rosebeck, Sandeep Gurbuxani, Dominik Dytfeld, Andrzej Jakubowiak	1
6	Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) 2016 ·Blood ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Craig E. Cole, Ajai Chari, Jennifer Nam, (unknown), (unknown), Kathryn McDonnell, Shaun Rosebeck, Todd M. Zimmerman, Theodore Karrison, Jeffrey A. Zonder	11
7	An Undergraduate Research Experience Studying Ras and Ras Mutants 2015 ·IEEE Transactions on Education ·Nancy D. Griffeth, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer Nam, (unknown), (unknown), (unknown), Dylan Sun	2
8	Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM) 2015 ·Blood ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Jeffrey A. Zonder, Craig E. Cole, Ajai Chari, Jennifer Nam, (unknown), Kathryn McDonnell, (unknown), Shaun Rosebeck, Tami Rashal, Hagop Youssoufian, Sarah Henry, Sharon Shacham, Michael Kauffman, Todd M. Zimmerman, Theodore Karrison	6
9	Accelerated repair of demyelinated CNS lesions in the absence of non‐muscle myosin IIB 2014 ·Glia ·Tomasz Rusielewicz, Jennifer Nam, (unknown), Gareth John, Cedric S. Raine, Carmen V. Melendez‐Vasquez	21
10	Serotonin Transporter Polymorphism Interacts With Childhood Adversity to Predict Aspects of Impulsivity 2011 ·Psychological Science ·Charles S. Carver, Sheri L. Johnson, Jutta Joormann, Youngmee Kim, Jennifer Nam	105
11	Lamotrigine plus Quetiapine Combination Therapy in Treatment-Resistant Bipolar Depression 2011 ·Annals of Clinical Psychiatry ·Yong Min Ahn, Jennifer Nam, Jenifer L. Culver, Wendy Marsh, (unknown), Terence A. Ketter	12
12	Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting 2010 ·Journal of Psychiatric Research ·Terence A. Ketter, John O. Brooks, Jennifer Hoblyn, (unknown), Jennifer Nam, Jenifer L. Culver, Wendy Marsh, (unknown)	6
13	Higher prevalence of bipolar I disorder among Asian and Latino compared to Caucasian patients receiving treatment 2010 ·Asia-Pacific Psychiatry ·(unknown), Meredith E. Childers, Po W. Wang, Jennifer Nam, Kristine L. Keller, Shelley J. Hill, Terence A. Ketter	4
14	Do positive emotions predict symptomatic change in bipolar disorder? 2009 ·Bipolar Disorders ·June Gruber, Jenifer L. Culver, Sheri L. Johnson, Jennifer Nam, Kristine L. Keller, Terence A. Ketter	40
15	Divalproex extended-release in acute bipolar II depression 2009 ·Journal of Affective Disorders ·Po W. Wang, Cecylia Nowakowska, Rebecca A. Chandler, Shelley J. Hill, Jennifer Nam, Jenifer L. Culver, Kristine L. Keller, Terence A. Ketter	7
16	Effectiveness of lamotrigine in bipolar disorder in a clinical setting 2008 ·Journal of Psychiatric Research ·Terence A. Ketter, John O. Brooks, Jennifer Hoblyn, (unknown), Jennifer Nam, Jenifer L. Culver, Wendy Marsh, (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact